f Post-Approval Studies (PAS) Database
  • Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Post-Approval Studies (PAS) Database

  • Print
  • Share
  • E-mail
-

The FDA has the authority to require sponsors to perform a post-approval study (or studies) at the time of approval of a premarket approval (PMA), humanitarian device exemption (HDE), or product development protocol (PDP) application. Post-approval studies can provide patients, health care professionals, the device industry, the FDA and other stakeholders information on the continued safety and effectiveness (or continued probable benefit, in the case of an HDE) of approved medical devices. This database allows you to search Post-Approval Study information by applicant or device information.

Learn more...


           

S.T.A.R. Ankle PAS


Suggest Enhancement / Report Issue | export reports to excelExport to Excel
General
Study Status Study Pending
Application Number /
Requirement Number
P050050 S024/ PAS001
Date Original Protocol Accepted 03/13/2024
Date Current Protocol Accepted  
Study Name S.T.A.R. Ankle PAS
Device Name Scandinavian Total Ankle Replacement System (S.T.A.R. Ankle)
General Study Protocol Parameters
Study Design Prospective Cohort Study
Data Source New Data Collection
Comparison Group Historical Control
Analysis Type Analytical
Study Population Adult: >21
Detailed Study Protocol Parameters
Study Objectives Study Objective: Demonstrate equal or better performance of the STAR TAR system with vitamin E (e+) mobile bearing relative to a historical control with respect to cumulative revision rate at 8 years post implantation.
Study Design: Prospective, Multicenter, Single-Arm, Comparative Observational Study
Study Population The study population includes adult subjects (aged 22 years and over) implanted with the STAR TAR System with the e+ mobile bearing for the treatment of painful arthritic ankle joints due to osteoarthritis, posttraumatic arthritis, or rheumatoid arthritis.
The comparator is a historical control group consisting of a cumulative revision rate for all fixed bearing ankles from the Australian Orthopaedic Association National Joint Replacement Registry (AOANJRR) at eight (8) years post-implantation.
Sample Size Number of Patients: 300 evaluable patients
Assumptions: The sample size is determined using a precision – based method assuming a revision rate of 4.5% for the STAR TAR system with e+ mobile bearing at 7 years follow-up, a 95% confidence interval with an upper confidence limit of 6.8%, and a type 1 error of 5%. To account for a 20% attrition rate, at least 375 patients will be enrolled in this study.
Number of Sites: 8 – 10 US Sites
Key Study Endpoints Primary Endpoints:
• Device cumulative revision rate of the STAR TAR system with e+ mobile bearing at eight (8) years post-implantation.
• Within the primary endpoint, a quantitative assessment of the polyethylene fracture rate of the subject device to the historical control data will be performed
Secondary Endpoints:
• Device revision rate assessed at all timepoints post-implantation
• Change from baseline for Total Buechel-Pappas Scale Score
• Change from baseline for Pain Visual Analog Scale (VAS) (100mm scale)
• Change from baseline for Quality of Life (SF-36)
• Change from baseline for American Orthopedic Foot & Ankle Society (AOFAS) Ankle Hindfoot Scale Score
• Radiographic endpoints (anterior-posterior and lateral x-ray images of the treated ankle)
o Quantitative and qualitative radiographic assessment of the total ankle arthroplasty including evaluation of both the femoral and tibial components, for the following outcomes:
. radiolucency and osteolysis
. subsidence
. migration
. rotation
. integrity.
. Assessment of polyethylene bearing for integrity (e.g., fracture, dislocation, subluxation, worn, intact).
• Explant analysis of any explanted devices and all revisions
• All adverse events including the nature, onset, duration, severity, and relationship to the device and/or procedure
Follow-up Visits and Length of Follow-up 8 years


S.T.A.R. Ankle PAS Reporting Schedule

Reporting Schedule
Report
Date Due
FDA Receipt
Date
Applicant's Reporting Status
6 month report 05/13/2024    
1 year report 11/12/2024    
2 year report 11/12/2025    
3 year report 11/12/2026    
4 year report 11/12/2027    


Contact Us

Mandated Studies Program
Food and Drug Administration
10903 New Hampshire Ave.
Silver Spring, MD 20993-0002
Email: MandatedStudiesPrograms@fda.hhs.gov

Additional Resources

-
-